Hansoh Pharmaceutical and GSK Ink Global Licensing Deal for Innovative ADC HS-20089
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) has entered into a licensing agreement with...
InxMed Presents Positive Data for FAK Inhibitor Ifebemtinib at ESMO 2023
China-based firm InxMed (Nanjing) Co., Ltd has updated two clinical studies for its first-in-class small-molecule...
Foundation Medicine Expands Genomic Profiling Partnership with Sequanta Technologies in China
US-based Contract Research Organization (CRO) Foundation Medicine Inc. has announced the expansion of its existing...
Jenscare’s LuX-Valve Plus Completes Compassionate Use Cases in Asia-Pacific
Jenscare Scientific Co., Ltd (HKG: 9877), a leading device maker specializing in structural heart disease...
Fosun Pharmaceutical to Acquire 14% Stake in UnitedHealthcare for USD 34 Million
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) has announced plans to invest RMB 248.9...
Beijing SL Pharmaceutical Gains NMPA Approval for Phase I Trial of MBT-1608 for Hepatitis C
China’s Beijing SL Pharmaceutical Co., Ltd (SHE: 002038) has announced that it has received approval...
Skyline Therapeutics Gains NMPA Approval for SKG0106 in Neovascular AMD Treatment
Skyline Therapeutics has announced that it has received clinical trial approval from the National Medical...
Accuredit Therapeutics Initiates First Dosing of Gene Therapy ART001 for ATTR
China-based gene therapy start-up Accuredit Therapeutics (Suzhou) Co., Ltd has announced the first dosing of...
Bayer HealthCare Launches First Innovation Center in Beijing’s ETown
Bayer HealthCare (ETR: BAYN) has formally inaugurated its inaugural innovation center in China, strategically situated...
China’s State Council Unveils Plan to Boost Patent Commercialization by 2025
China’s State Council has recently approved the “Special Action Plan for Patent Commercialization and Utilization...
BMS’s Sotyktu Receives NMPA Approval for Psoriasis Treatment
The National Medical Products Administration (NMPA) has granted regulatory approval to US-based pharmaceutical major Bristol-Myers...
CDE Grants Priority Review to Pearl Biotech’s Breatinib for Glioblastoma Treatment
China’s Center for Drug Evaluation (CDE) has indicated that Beijing Pearl Biotechnology Co., Ltd’s breatinib...
Roche’s Q3 2023 Report Shows 1% Global Growth Amid Lower COVID-19 Product Demand
Swiss pharmaceutical giant Roche (SWX: ROG) released its Q3 2023 report, indicating that a reduced...
BMS’s Subcutaneous Opdivo Meets Phase III Study Endpoints in ccRCC
Bristol-Myers Squibb (BMS; NYSE: BMY) has announced positive results from a Phase III comparative study...
Novo Nordisk Partners with GE HealthCare to Develop Non-Invasive Treatment for Chronic Diseases
Metabolism expert Novo Nordisk (NYSE: NVO) has announced a partnership with medical technology firm GE...
MSD Collaborates with Daiichi Sankyo on Development of Innovative ADC Candidates
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced a strategic collaboration agreement with Japan-based...
HuidaGene Receives FDA Rare Pediatric Disease Designation for MECP2 Syndrome Therapy
China-based HuidaGene (Shanghai) Biotechnology Co., Ltd has announced that it has received Rare Pediatric Disease...
Kyowa Hakko Kirin Doubles Manufacturing Capacity with Shanghai Plant Expansion
Japan-based biopharmaceutical company Kyowa Hakko Kirin has announced the successful completion and operational status of...
Sansure Biotech Partners with Shaanxi Lifegen to Boost Molecular Diagnostics
China-based molecular diagnostics specialist Sansure Biotech Inc. (SHA: 688289) has formed a strategic partnership with...
Alebund Pharmaceuticals Secures Exclusive Rights to Roche’s Mircera in China
Shanghai-based Alebund Pharmaceuticals has entered into a commercialization agreement with Swiss pharmaceutical giant Roche (SWX:...